Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Japanese Lung Cancer Registry Study Prognosis of 13,010 Resected Lung Cancers

A Japanese Lung Cancer Registry Study Prognosis of 13,010 Resected Lung Cancers ORIGINAL ARTICLE A Japanese Lung Cancer Registry Study Prognosis of 13,010 Resected Lung Cancers Hisao Asamura, MD,* Tomoyuki Goya, MD,† Yoshihiko Koshiishi, MD,† Yasunori Sohara, MD,‡ Kenji Eguchi, MD,§ Masaki Mori, MD, Yohichi Nakanishi, MD,¶ Ryosuke Tsuchiya, MD,* Kaoru Shimokata, MD,# Hiroshi Inoue, MD,**†† Toshihiro Nukiwa, MD,‡‡ and Etsuo Miyaoka, MD,‡‡ for the Japanese Joint Committee of Lung Cancer Registry 32.6% (n  526) and 29.6% (n  1108) for IIIB, and 26.5% (n Purpose: The validation of tumor, node, metastasis staging system 198) and 23.1% (n  375) for IV. Adenocarcinoma, female in terms of prognosis is an indispensable part of establishing a better gender, and age less than 50 years were significant favorable staging system in lung cancer. prognostic factors. Methods: In 2005, 387 Japanese institutions submitted informa- Conclusion: This large registry study provides benchmark prognos- tion regarding the prognosis and clinicopathologic profiles of tic statistics for lung cancer. The prognostic difference between patients who underwent pulmonary resections for primary lung stages IB and IIA was small despite different stages. Otherwise, the neoplasms in 1999 to the Japanese Joint Committee of Lung present tumor, node, metastasis staging system well characterizes Cancer Registry. The data of 13,010 patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

A Japanese Lung Cancer Registry Study Prognosis of 13,010 Resected Lung Cancers

Miyaoka, Etsuo
Journal of Thoracic Oncology , Volume 3 (1) – Jan 1, 2008
Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/a-japanese-lung-cancer-registry-study-prognosis-of-13-010-resected-eYJwNwQEJQ

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31815e8577
pmid
18166840
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE A Japanese Lung Cancer Registry Study Prognosis of 13,010 Resected Lung Cancers Hisao Asamura, MD,* Tomoyuki Goya, MD,† Yoshihiko Koshiishi, MD,† Yasunori Sohara, MD,‡ Kenji Eguchi, MD,§ Masaki Mori, MD, Yohichi Nakanishi, MD,¶ Ryosuke Tsuchiya, MD,* Kaoru Shimokata, MD,# Hiroshi Inoue, MD,**†† Toshihiro Nukiwa, MD,‡‡ and Etsuo Miyaoka, MD,‡‡ for the Japanese Joint Committee of Lung Cancer Registry 32.6% (n  526) and 29.6% (n  1108) for IIIB, and 26.5% (n Purpose: The validation of tumor, node, metastasis staging system 198) and 23.1% (n  375) for IV. Adenocarcinoma, female in terms of prognosis is an indispensable part of establishing a better gender, and age less than 50 years were significant favorable staging system in lung cancer. prognostic factors. Methods: In 2005, 387 Japanese institutions submitted informa- Conclusion: This large registry study provides benchmark prognos- tion regarding the prognosis and clinicopathologic profiles of tic statistics for lung cancer. The prognostic difference between patients who underwent pulmonary resections for primary lung stages IB and IIA was small despite different stages. Otherwise, the neoplasms in 1999 to the Japanese Joint Committee of Lung present tumor, node, metastasis staging system well characterizes Cancer Registry. The data of 13,010 patients

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jan 1, 2008

References

  • Lung tumours
    International Union Against Cancer
  • Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study
    Goya
  • How should the TNM staging system for lung cancer be revised? A simulation based on the Japanese Lung Cancer Registry populations
    Asamura